Additional Relevant Details U.S. Patent and Trademark Office has issued U.S. Patent No. 9,249,191, Virus Like Particle Composition. The patent protects key composition of matter of VLP’s proprietary i-α virus like particles platform technology, and the pharmaceutical composition and vaccine for use in the prevention and/or treatment of various diseases. Utilizing this platform technology, VLP is currently developing preventative and therapeutic vaccines as well as next generation of targeted antibody agents to treat cancer, infectious diseases, such as Malaria, Dengue Fever and Zika virus disease, and auto-immune and neurological diseases.